SecBot SecBot
Insider Cluster (2 insiders) ·Filed Sep 16, 2026

AQST

Aquestive Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $166K total
Actionable Insight • Neutral

The insider sales are trivial in dollar terms and likely liquidity/vesting-driven (single CCO sale plus a small cluster) — no bearish read-through.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d
AQST ▼ -3.11% at T+20d
NEUTRAL call -3.11% · α vs SPY -6.29% · entry $4.82 → $4.67
Next anchor: T+60d in 6w
Latest observation: T+27 -17.05% FF3 residual α
Entry = T+0 close
Sep 16, 2026
via day close
T+1d
-3.32%
call -3.32% · α -4.45%
$4.66
settled 6w ago
T+5d
-2.49%
call -2.49% · α -5.05%
$4.70
settled 5w ago
T+20d
-3.11%
call -3.11% · α -6.29%
$4.67
settled 12d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

Insider cluster at Aquestive (AQST) is dominated by a single open-market SELL from CCO Sherry Korczynski ($46K) plus a small $166K cluster of 2 sales in the last 30 days — both immaterial relative to the company's ~$326M market cap (~0.05% combined). The cluster is small, includes a C-suite officer, and shows no buying. Per the asymmetric calibration, insider sells are weak predictors (often liquidity/vesting-driven), and this cluster is too small to move the stock.

Key Financial Metrics

Direction
selling
Total Value
$166.0K
Insiders
2

Key Facts

  • CCO Sherry Korczynski sold 8.8K shares at $5.22 for ~$46K on 2026-09-09 (open-market sale, code S).
  • Total insider activity in the last 30 days: 2 sells totaling ~$166K — under 0.1% of the ~$326M market cap, well below the materiality threshold.
  • No insider purchases in the cluster; no C-suite buys to offset the sales.
  • Analyst consensus is 93% bullish (4 Strong Buy, 10 Buy, 1 Hold), but insider activity shows no buying to confirm.
  • Institutional 13F shows mixed positioning: 4 adds, 10 trims, 5 doubled, 1 near-exit — no clear accumulation signal.

Financial Impact

~$166K total insider sales over 30 days, ~0.05% of market cap — immaterial

insider_sellingliquidity

Risk Factors

  • Insider sales, though small, could precede a broader sell-off if the stock has run up — but no evidence of that here.
  • No insider buying means management is not signaling conviction at current levels.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-AQST-1789581676140
18 reports for AQST
Performance horizon
63% Hit rate @ T+5 5 of 8 directional calls Went positive at some point 6 of 8 best @ T+20▲ +21.45%Aug 10, 2026
Filters
Rows
Reports for AQST — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
8-K
BULLISH ★ 7/10
$4.06 $4.13▲ +1.72%▲ +2.74%$3.97 (−2.22%)
Oct 15, 2026
11d ago
Press Release
BULLISH ★ 7/10
$4.06 $4.13▲ +1.72%▲ +2.74%$3.97 (−2.22%)
Oct 14, 2026
12d ago
8-K
BULLISH ★ 6/10
$4.61 $4.08▼ −11.50%▼ −11.95%$3.97 (−13.88%)
Oct 7, 2026
19d ago
SC 13G
NEUTRAL ★ 3/10
$4.62 $4.61▼ −0.22%▲ +0.76%$3.97 (−14.07%)
Oct 7, 2026
19d ago
SC 13G/A
BEARISH ★ 6/10
$4.62 $4.61▲ +0.22%▼ −0.76%$3.97 (+14.07%)
Sep 29, 2026
27d ago
8-K
NEUTRAL ★ 2/10
$4.67 $4.61▼ −1.28%▼ −3.23%$3.97 (−14.99%)
Sep 25, 2026
4w ago
8-K
NEUTRAL ★ 5/10
$4.68 $4.55▼ −2.78%▼ −2.56%$3.97 (−15.17%)
Sep 17, 2026
5w ago
8-K
BULLISH ★ 7/10
$4.66 $4.82▲ +3.43%▲ +2.83%$3.97 (−14.81%)
Sep 16, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$4.82 $4.70▼ −2.49%▼ −5.05%$3.97 (−17.63%)
Aug 15, 2026
10w ago
Institutional Cluster
MIXED ★ 4/10
$4.29 $4.80▲ +11.89%▲ +13.08%$3.97 (−7.46%)
Showing 10 of 18

US Market Status

Market Closed — Opens Tue (16h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 16, 2026